Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis

Table 1 Histological grading and staging in CCl₄-induced specimens after 8 week treatment

Groups	2g*	2s*	SSS△
Normal control group	1.00 ± 0.00	1.00 ± 0.00	0
Fibrotic model group	9.20 ± 5.01	10.40 ± 5.06	14.60 ± 7.82
Colchicine treatment group	10.40 ± 5.06	7.40 ± 4.99a	10.60 ± 3.34a
High-dose IFN-γ group	9.60 ± 3.37	3.00 ± 1.05bc	5.10 ± 2.88bc
Medium-dose IFN-γ group	6.00 ± 4.22	5.60 ± 4.20bc	7.70 ± 3.53bc
Low-dose IFN-γ group	7.60 ± 4.79	5.40 ± 2.32bc	8.00 ± 3.30bc

*Scheuer’s criteria;

^△Chevallier’s criteria;

^aP < 0.05 vs fibrotic model group;

^bP < 0.01 vs fibrotic model group;

^cP < 0.05 vs colchicines treatment group.

Table 2 Histological grading and staging in DMN-induced specimens after 4 week treatment

Groups	2g*	2s*	SSS△
Normal control group	1.00 ± 0.00	1.00 ± 0.00	0
Fibrotic model group	7.00 ± 2.16	9.60 ± 4.70	12.60 ± 3.57
Colchicine treatment group	6.80 ± 4.13	7.00 ± 3.92a	11.30 ± 2.37a
High-dose IFN-γ group	6.40 ± 2.07	2.60 ± 0.97bc	6.30 ± 0.48bc
Medium-dose IFN-γ group	4.80 ± 2.35	4.00 ± 2.32bc	8. 10 ± 2.72bc
Low-dose IFN-γ group	5.00 ± 2.71	4.40 ± 2.07bc	8.30 ± 2.58bc

*Scheuer’s criteria;

^△Chevallier’s criteria;

^aP < 0.05 vs fibrotic model group;

^bP < 0.01 vs fibrotic model group;

^cP < 0.05 vs colchicines treatment group.

Table 3 Serum hyaluronic acid level and liver hydroxylproline content in CCl₄-induced specimens after 8 weeks treatment

Groups	HA (μg/L)	Hyp (mg/g liver dry weight)
Normal control group	147.64 ± 19.28	2.43 ± 0.33
Fibrotic model group	900.04 ± 508.84	10.01 ± 3.23
Colchicine treatment group	745.57 ± 170.44a	6.90 ± 1.70
High-dose IFN-γ group	482.05 ± 210.57	2.83 ± 1.18
Medium-dose IFN-γ group	765.51 ± 586.65a	3.59 ± 1.22bd
Low-dose IFN-γ group	981.52 ± 509.95	4.80 ± 1.62

^aP < 0.05 vs fibrotic model group;

^bP < 0.01 vs fibrotic model group; ^cP < 0.05 vs colchicines treatment group;

^dP < 0.01 vs colchicines treatment group.

Table 4 Serum hyaluronic acid level and liver hydroxylproline content in DMN-induced specimens after 4-weeks treatment

Groups	HA (μg/L)	Hyp (mg/g liver dry weight)
Normal control group	147.64 ± 19.28	2.43 ± 0.33
Fibrotic model group	969.52 ± 257.80	12.79 ± 1.54
Colchicine treatment group	323.72 ± 388.45a	6.40 ± 1.84a
High-dose IFN-γ group	144.25 ± 105.66	2.72 ± 0.58
Medium-dose IFN-γ group	334.10 ± 420.06	3.14 ± 0.71
Low-dose IFN-γ group	407.95 ± 386.61a	3.62 ± 1.02bd

^aP < 0.05 vs fibrotic model group;

^bP < 0.01 vs fibrotic model group; ^cP < 0.05 vs colchicines treatment group;

^dP < 0.01 vs colchicines treatment group.

Table 5 Symptom change after IFN-γ treatment

	Fatigue	Abdominal distention	Nausea	Liver area pain
Before treatment	33	31	12	22
After treatment	4	4	0	4

Table 6 Histological grading and staging of liver biopsy specimens before and after 9-month treatment

	Grade*	Score of grade△	Stage*	Score of stage△
Before treatment	2.30 ± 0.98	7.30 ± 5.39	2.60 ± 0.88	8.40 ± 5.83
After 9-month treatment	1.95 ± 0.69	4.90 ± 2.27	2.05 ± 0.76	5.30 ± 4.05
t		2.719		2.719
P		0.051		0.014a

*Scheuer’s criteria; ^△Chevallier’s criteria; ^aP < 0.05 vs before treatment

Table 7 Serum hepatic fibrosis indices before and after 9-month treatment

Hepatic fibrosis indices	HA (μg/L)	LN (μg/L)	PCIII (μg/L)	C-IV (μg/L)
Before treatment	435.38 ± 373.00	161.22 ± 41.02	192.59 ± 89.95	156.30 ± 44.01
After 9-month treatment	281.57 ± 220.48	146.35 ± 44.67	156.98 ± 49.22	139.14 ± 34.47
t	2.341	2.434	2.381	2.104
P	0.017a	0.021a	0.020a	0.038a

^aP < 0.05 vs before treatment.